Blood & Cancer
161 episodes - English - Latest episode: almost 3 years ago - ★★★★★ - 31 ratingsThe official podcast feed of MDedge Hematology-Oncology, part of the Medscape Professional Network. On Thursdays, Dr. David Henry interviews key opinion leaders and rising stars in hematology and oncology. The information in this podcast is provided for informational and educational purposes only.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Biosimilars with Dr. Gary Lyman
May 27, 2021 08:00 - 32 minutes - 44.1 MBExisting biosimilars are safe, effective alternatives to their reference biologics, and are increasingly being incorporated into oncology treatment guidelines. Technological advances that have emerged in the years since biologic agents entered the market allow for the careful assessment of “critical clinical attributes” of biosimilar agents. This helps ensure the safety and efficacy of biosimilars, as well as their structural, functional, and behavioral similarities to the original referen...
Advanced bladder cancer: Dr. Arjun Balar talks treatment strategies in a changing field
May 20, 2021 08:00 - 27 minutes - 37.7 MBSystemic treatment for advanced urothelial cancer is quickly evolving. On this week’s podcast, Arjun Balar, MD, director of the genitourinary medical oncology program at New York University discusses his approach amid changing times with guest host Alan Lyss, MD, a community-based medical oncologist and clinical researcher in the St. Louis area before his recent retirement. Chemotherapy or immunotherapy first line? With the negative phase 3 results for chemotherapy in combination with ei...
Gene therapies in hemophilia with Dr. Glenn Pierce
May 13, 2021 08:00 - 24 minutes - 33.2 MBA “very basic” type of gene therapy could potentially cure hemophilia, but a major hurdle has been the lack of an effective mode of delivery. Recent strides in using adeno-associated virus (AAV) vectors are changing that, and Glenn Pierce, MD, World Federation of Hemophilia Vice President, Medical, predicts approvals in the next 12-18 months. Dr. Pierce shared his personal experience with hemophilia and discussed his and others’ ongoing research on the use of AAV-mediated gene therapy with...
Thrombosis and thrombocytopenia caused by COVID-19 vaccines: How to identify and treat VITT, VIPIT, or TTS
May 06, 2021 08:00 - 23 minutes - 31.8 MBAt least 17 cases of thrombosis and thrombocytopenia have been reported in patients who received the Johnson & Johnson COVID-19 vaccine in the United States. Such events have been reported in patients who received the AstraZeneca vaccine as well. In this episode, Adam C. Cuker, MD, of the University of Pennsylvania, Philadelphia, tells host David H. Henry, MD, how to identify and manage patients with these vaccine-induced events. What’s in a name? The phenomenon of vaccine-induced ...
Toward more personalized treatment in prostate cancer: The CCR score predicts metastasis and guides treatment decisions after radiation
April 29, 2021 08:00 - 28 minutes - 39 MBThe combined clinical cell-cycle risk (CCR) score uses clinical and genetic factors to assess the risk of metastasis after radiation therapy in patients with prostate cancer. The CCR score has proven accurate in studies and can guide post-radiation treatment decisions in practice, according to Jonathan D. Tward, MD, PhD, of the University of Utah, Salt Lake City. Dr. Tward discusses the CCR score with host David Henry, MD, in this episode. About the score The CCR score combines the c...
Changing perspectives: Dr. Michael Weiner recounts his experiences as an oncologist who became a cancer patient and then a caregiver
April 22, 2021 08:00 - 25 minutes - 35 MBPediatric oncologists are used to dealing with emotional, heart-wrenching situations, but oncology took on a new dimension for Michael Weiner, MD, when both he and his daughter were diagnosed with cancer. Dr. Weiner, a pediatric oncologist at Columbia University, New York, describes his roles as oncologist, patient, and caregiver to host David H. Henry, MD, in this episode. Oncologist as patient: Lessons learned Dr. Weiner’s journey as a cancer patient began when he felt a lymph node o...
Optimizing CAR T-cell therapies in lymphoma: Improving response, fighting cytokine release syndrome, and identifying mechanisms of resistance
April 15, 2021 08:00 - 25 minutes - 35.2 MBStudies have shown that chimeric antigen receptor (CAR) T-cell therapies produce responses in patients with relapsed/refractory B-cell lymphomas, but researchers continue to look for ways to improve efficacy, decrease toxicity, and overcome treatment resistance. Leslie Kean, MD, PhD, of Boston Children’s Hospital, discusses some of this research with host David H. Henry, MD, in this episode. Dr. Kean outlines four recent studies of CAR T-cell therapies in lymphoma. The studies were selec...
Trends in genetic testing for breast and ovarian cancer: Undertesting and racial/ethnic disparities persist
April 08, 2021 08:00 - 26 minutes - 36.7 MBResearchers have tracked the evolution of genetic germline testing in women with breast or ovarian cancer in recent years and reported the results in the Journal of Clinical Oncology. Study author Allison W. Kurian, MD, of Stanford (Calif.) University, describes the group’s findings (https://bit.ly/31RaSGR) to guest host Alan Lyss, MD, subprincipal investigator emeritus for Heartland Cancer Research NCORP, in this episode. Study rationale and methods Dr. Kurian said that an inflection ...
Improving cancer screening in the COVID era: Drive By Flu-FIT allows for socially distanced colorectal cancer screening
April 01, 2021 08:00 - 25 minutes - 34.3 MBA program called Drive By Flu-FIT has allowed for socially distanced colorectal cancer (CRC) screening during the COVID-19 pandemic. Armenta Washington, senior research coordinator at the University of Pennsylvania, describes the program to guest host Alan Lyss, MD, subprincipal investigator emeritus for Heartland Cancer Research NCORP, in this episode. What is Drive By Flu-FIT? Drive By Flu-FIT is a socially distanced version of the Flu-Fecal Immunochemical Test (Flu-FIT) program. Fl...
Unpacking von Willebrand disease guidelines: Dr. Paula James talks diagnosis and pre-procedure prophylaxis
March 25, 2021 08:00 - 18 minutes - 25.6 MBEarlier this year, clinical practice guidelines for the diagnosis and management of von Willebrand disease (VWD) were published in Blood Advances. The guidelines (https://bit.ly/2OIfKLE) are a collaborative effort from the American Society of Hematology, the International Society on Thrombosis and Haemostasis, the National Hemophilia Foundation, and the World Federation of Hemophilia. Guideline author Paula James, MD, of Queens University, Kingston, Ont., reviews some of the recommendati...
FDA approvals in hematology and oncology, Part II: New oral formulations, RET and MET inhibitors, and CAR T-cell therapies
March 18, 2021 08:00 - 20 minutes - 27.8 MBWe continue our review of drugs recently approved by the Food and Drug Administration (FDA) in the hematology/oncology space. In part 1 of our review, David M. Mintzer, MD, of Pennsylvania Hospital, highlighted 11 therapies, including newly-approved treatments and new indications for older drugs. Part 1 was published Feb. 18 (https://bit.ly/38JR782). Now, in part 2, Dr. Mintzer tells host David H. Henry, MD, about another 11 therapies recently approved by the FDA, including monoclonal ...
How I treat CLL and MCL: From ‘watch and wait’ to BCL2 and BTK inhibitors, CAR T-cell therapy, and transplant
March 11, 2021 09:00 - 22 minutes - 31.4 MBTreatments for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) have advanced in recent years, with more new developments on the horizon. James Gerson, MD, of the University of Pennsylvania, Philadelphia, reviewed some of these advances and future directions while describing how he would treat three patients. Host David H. Henry, MD, posed the following cases for consideration. Case 1 In a 75-year-old male with no comorbid illness, routine blood work revealed a WBC cou...
COVID-19 vaccination in cancer patients: Who should be vaccinated and when?
March 04, 2021 09:00 - 30 minutes - 42.1 MBWhen should cancer patients receive a COVID-19 vaccine? The National Comprehensive Cancer Network (NCCN) has issued recommendations to provide guidance on the topic. Guideline author Steven Pergam, MD, of Fred Hutchinson Cancer Research Center, Seattle, explains NCCN’s recommendations to host David H. Henry, MD, in this episode. Prioritization Prioritization for COVID-19 vaccination should be given to cancer patients currently receiving chemotherapy, those who just finished active tr...
Managing pain in sickle cell crisis with Dr. Ifeyinwa Osunkwo
February 25, 2021 09:00 - 26 minutes - 35.8 MBIfeyinwa (Ify) Osunkwo, MD, MPH, joins us to talk about her approach to pain management in patients suffering from sickle cell crisis as well as the cognitive and behavioral effects of long-term opioid use in these patients. She and our host David H. Henry, MD, cover these topics and more in this episode. Dr. Osunkwo is a professor of medicine at Atrium Health and the director of the Sickle Cell Enterprise at the Levine Cancer Institute, part of Atrium Health, in Charlotte, N.C. Over the ...
FDA approvals in hematology and oncology: Novel agents and new tricks for old drugs
February 18, 2021 09:00 - 23 minutes - 32.1 MBIn this episode, we review drugs recently approved by the Food and Drug Administration in the hematology/oncology space. David M. Mintzer, MD, of Pennsylvania Hospital, joins host David H. Henry, MD, to highlight some first-time approvals and new indications for older drugs. Approvals in 2020 Pembrolizumab (Keytruda) was approved for a range of new indications last year, including: First-line treatment of patients with unresectable or metastatic microsatellite instability–high or mis...
NCI-MATCH trial reveals actionable mutations and matches cancer patients to targeted therapies
February 11, 2021 09:00 - 20 minutes - 27.7 MBThe NCI-MATCH trial was designed to reveal mutations in underexplored cancer types, allowing researchers to match patients to appropriate targeted therapies. Study investigator Alice P. Chen, MD, from the National Cancer Institute, reviews the goals and results of NCI-MATCH with host David H. Henry, MD, in this episode. Trial details NCI-MATCH has more than 1,000 participating sites. The trial is open to patients with advanced cancers that have progressed on standard treatment or rare...
COVID-19 vaccine 101: Dr. Drew Weissman discusses mechanisms, efficacy, and vaccinating patients with cancer or HIV
February 04, 2021 09:00 - 23 minutes - 32.6 MBHow do the various COVID-19 vaccines work, and when should patients be vaccinated? We tackle these topics and more in this episode. Our host David H. Henry, MD, is joined by Drew Weissman, MD, PhD, a professor at the University of Pennsylvania, Philadelphia. Dr. Weissman codeveloped the messenger RNA (mRNA) technology being used in the COVID-19 vaccines produced by Pfizer/BioNTech and Moderna. History of mRNA vaccines Testing of mRNA vaccines began in the 1990s. An initial problem w...
Barriers to clinical trial enrollment for patients with gynecologic cancers: Why patients don’t participate and how to improve enrollment
January 28, 2021 09:00 - 21 minutes - 29.7 MBThe greatest barrier to clinical trial enrollment is patients not knowing an appropriate trial exists, according to a survey of gynecologic cancer survivors. The most common reason survey respondents gave for not enrolling in clinical trials was that their medical team didn't tell them about any trials. Annie Ellis and Mary (Dicey) Jackson Scroggins – who are both patient advocates and ovarian cancer survivors – conducted this survey and presented the results at the Society of Gynecolo...
Convalescent plasma for COVID-19, race linked to cancer-associated thrombosis risk, iron deficiency common in pregnancy, and more from ‘Best of ASH’
January 21, 2021 09:00 - 18 minutes - 26.1 MBNew studies have shed additional light on how convalescent plasma may affect patients with COVID-19, how blood type impacts bleeding risk, the effects of race on cancer-associated thrombosis, and iron deficiency in pregnancy. These studies were presented as part of the “Best of ASH” session at the 2020 annual meeting of the American Society of Hematology. Alisa S. Wolberg, PhD, of the University of North Carolina at Chapel Hill, who cochaired the session, reviews these studies with host ...
Thrombosis research from ASH 2020: Khorana score falls short in cancer study, factors predict VTE in cancer patients with COVID-19, and antithrombotics don’t affect severe COVID outcomes
January 14, 2021 09:00 - 24 minutes - 33.7 MBThree studies revealed new findings on thrombosis in patients with cancer and/or COVID-19. These studies were presented at the 2020 annual meeting of the American Society of Hematology. One study suggested the Khorana score may be ineffective for predicting venous thromboembolism (VTE) in cancer patients. Another study revealed factors that can predict VTE in patients with cancer and COVID-19. And a third study indicated that antithrombotic agents don’t improve outcomes in patients with se...
Highlights from SABCS 2020: New data on CDK4/6 inhibitors, omitting chemotherapy and radiotherapy, underreporting toxicity, and predicting outcomes in breast cancer
January 07, 2021 09:00 - 52 minutes - 71.7 MBA number of groundbreaking and practice-changing studies were presented at the San Antonio Breast Cancer Symposium 2020. The RxPONDER, ADAPT, and PRIME-2 trials revealed patients who can forgo chemotherapy or radiotherapy, monarchE and PENELOPE-B showed conflicting results with CDK4/6 inhibitors, one study indicated that a new tool can guide adjuvant chemotherapy, and another study suggested that circulating tumor cells (CTCs) can predict overall survival (OS). Alan P. Lyss, MD, subprinc...
Best of Blood & Cancer 2020
December 24, 2020 09:00 - 40 minutes - 55.5 MBIn this episode, we bring you clips from the best Blood & Cancer shows of 2020. Blood & Cancer will be back with new episodes in 2021. ESMO 2020: Late-breaking and practice-changing studies on COVID-19 and breast, lung, gastrointestinal, and other cancers https://bit.ly/3h7aWZM Beyond the lungs: How COVID-19 affects the blood, brain, gastrointestinal system, and other organ systems https://bit.ly/37GhV8Q EHA25: AML, myeloma, polycythemia vera, and COVID-19 with EHA President John Gribb...
SABCS 2020: More women may forgo chemo, surgery's role in opioid use, and pregnancy after breast cancer
December 22, 2020 09:00 - 7 minutes - 10.8 MBNews from SABCS 2020: RxPONDER: Even more women may forgo chemo for breast cancer: https://bit.ly/2LIYjZt Breast surgery may be a gateway to addictive medication use: https://bit.ly/3gSWfJF Pregnancy after breast cancer is rockier but doesn’t increase recurrence risk: https://bit.ly/2KwlhCx Email Blood & Cancer at [email protected].
How does COVID-19 affect patients with hematologic malignancies? The ASH registry provides some answers
December 17, 2020 09:00 - 26 minutes - 36.5 MBThe ASH Research Collaborative COVID-19 Registry for Hematology was established earlier this year to study patients with hematologic malignancies diagnosed with COVID-19. Now, the registry also includes patients with nonmalignant hematologic disorders and hematologic manifestations of COVID-19. William Wood, MD, of the University of North Carolina at Chapel Hill, recently presented data from the registry at the ASH Annual Meeting. In this episode, Dr. Wood tells host David H. Henry, MD, ho...
News from ASH 2020: 'Practice-changing' results with ruxolitinib in chronic GVHD and no benefit seen with tranexamic acid in patients with blood cancers and severe thrombocytopenia
December 15, 2020 09:00 - 9 minutes - 13.3 MBNews from ASH 2020: No benefit from tranexamic acid prophylaxis in blood cancers: https://bit.ly/2K3Mah1 ‘Practice changing’: Ruxolitinib as second-line in chronic GVHD: https://bit.ly/3gT4kyg Durable responses with anti-BCMA CAR T-cell for multiple myeloma: https://bit.ly/381f1ut Five-minute SC injection of daratumumab in RRMM: https://bit.ly/3gKuZgx Email Blood & Cancer at [email protected]
How I treat GVHD: Dr. James Ferrara explains how biomarkers can predict outcomes and guide the treatment of acute GVHD
December 10, 2020 09:00 - 28 minutes - 39 MBA pair of biomarkers are being used to guide treatment and predict mortality in patients with graft-versus-host disease (GVHD), according to James L.M. Ferrara, MD, DSc, of the Icahn School of Medicine at Mount Sinai, New York. In this episode, Dr. Ferrara explains how measuring these biomarkers – REG3-alpha and ST2 – can prevent over- and undertreatment of acute GVHD. The biomarkers have also been shown to predict nonrelapse mortality more accurately than a change in clinical symptoms. ...
Black patients with ES-SCLC get less chemo, CTCs may guide breast cancer treatment, and new FDA approvals for neuroblastoma and prostate cancer
December 08, 2020 09:00 - 8 minutes - 11.7 MBBlood & Cancer news stories: Black patients with ES-SCLC get less chemo but have better survival: https://bit.ly/33Rb5eB Should CTCs guide treatment choice in HR+, HER2– breast cancer?: https://bit.ly/3gn6shc New drug approved for relapsed/refractory neuroblastoma: https://bit.ly/2VMpvIy FDA approves first agent for PSMA-PET imaging in prostate cancer: https://bit.ly/36TAaY7 Contact Blood & Cancer at [email protected].
Can aerosolized chemotherapy better treat peritoneal carcinomatosis in patients with gynecologic or gastrointestinal cancers?
December 03, 2020 09:00 - 22 minutes - 30.2 MBResearchers are conducting the first U.S. trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) for the treatment of peritoneal carcinomatosis in patients with gynecologic or gastrointestinal cancers. Coprincipal investigator Thanh H. Dellinger, MD, of City of Hope in Duarte, Calif., describes this trial and the PIPAC procedure to host David H. Henry, MD, in this episode. To start, the pair discuss a patient who might be eligible for PIPAC – one with stage 3 ovarian cance...
News | Checkpoint inhibitors and COVID-19 mortality; HCC rates slow in cities, continue to climb in rural areas
December 01, 2020 09:00 - 8 minutes - 14 MBBlood & Cancer News Stories: Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest: https://bit.ly/2JlP2FN HCC rates slow in cities, continue to climb in rural areas: https://bit.ly/2Jx6Ux1 Risk factors for severe immune-related AEs identified: https://bit.ly/3fO6Fd8 Contact Blood & Cancer at [email protected]
Journal highlights with Dr. David Henry: Managing hematologic conditions in pregnancy, combo for elderly AML, genomics in DLBCL, and COVID-19 updates
November 26, 2020 09:00 - 11 minutes - 15.5 MBIn this episode, host David H. Henry, MD, highlights some recent articles from Blood, the Journal of Clinical Oncology, and the New England Journal of Medicine. Blood How I Treat series on hematologic complications in pregnancy. https://bit.ly/3fr5nV8 Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia. https://bit.ly/3nQvhF6 Journal of Clinical Oncology Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provision...
Cancer and hepatitis B virus: ASCO's recommendations for HBV screening, monitoring for reactivation, and how to treat patients
November 19, 2020 09:00 - 23 minutes - 31.6 MBIn this episode, we discuss updated guidelines on the screening and management of hepatitis B virus (HBV) in patients about to start anticancer therapy. The guidelines come from an American Society of Clinical Oncology Provisional Clinical Opinion (PCO) published earlier this year. Jessica P. Hwang, MD, of MD Anderson Cancer Center, and Andrew Artz, MD, of City of Hope, are cochairs of the ASCO PCO. They joined host David H. Henry, MD, to discuss the guidelines. Epidemiology of HBV Data...
How to kill a trial
November 17, 2020 09:00 - 7 minutes - 9.83 MBThe Tomosynthesis Mammography Imaging Screening Trial (TMIST) was designed to see if 3-D mammography, or tomosynthesis, could help personalize screening and if 3-D is actually better than the less expensive 2-D mammography. TMIST is the largest breast cancer screening trial in the United States, with a cost of $100 million and a planned enrollment of 165,000 women. There's just one problem. The study is falling short on enrollment of patients and participating sites. Will this mean the d...
Post-HSCT care at home: Can maintaining the patient’s microbiome prevent GVHD, improve other outcomes, decrease costs, and reduce the risk of COVID-19?
November 12, 2020 09:00 - 28 minutes - 38.6 MBCan receiving all posttransplant care at home benefit patients undergoing hematopoietic stem cell transplant (HSCT)? Researchers are conducting phase 2 trials to find out. Anthony D. Sung, MD, of Duke University School of Medicine, described this research to host David H. Henry, MD. Dr. Sung outlined the process of receiving post-HSCT care at home and discussed Duke's clinical trials assessing the impact of home care on costs, quality of life, the microbiome, and graft-versus-host diseas...
Real-world checkpoint inhibitor results not as good as trial results
November 10, 2020 09:00 - 9 minutes - 14.5 MBHematology Oncology News: IMRT new standard of care for high-risk cervical cancer: https://bit.ly/3k7ji3y Real-world results with checkpoint inhibitors found inferior to trial results: https://bit.ly/35cIt0v Are HMAS appropriate for posttransplant maintenance in acute leukemias?: https://bit.ly/3lfqsE7 You can email the show at [email protected].
How I treat NSCLC in the era of PD-L1 inhibitors and the COVID-19 pandemic
November 05, 2020 09:00 - 31 minutes - 45 MBIn this episode, we review how PD-L1 inhibitors and COVID-19 have changed the management of non-small cell lung cancer (NSCLC). Jeffrey Crawford, MD, and Susan Blackwell, PA, both of Duke Cancer Institute, join host David H. Henry, MD, to discuss the use of pembrolizumab in NSCLC, two studies of PD-L1 inhibitors presented at ESMO 2020, and how COVID-19 has affected NSCLC care, particularly the use of granulocyte colony-stimulating factor (G-CSF). Diagnosis and treatment of NSCLC What...
How I treat NSCLC in the era of checkpoint inhibitors and the COVID-19 pandemic
November 05, 2020 09:00 - 31 minutes - 45 MBIn this episode, we review how immune checkpoint inhibitors and COVID-19 have changed the management of non-small cell lung cancer (NSCLC). Jeffrey Crawford, MD, and Susan Blackwell, PA, both of Duke Cancer Institute, join host David H. Henry, MD, to discuss the use of pembrolizumab in NSCLC, two studies of PD-1 inhibitors presented at ESMO 2020, and how COVID-19 has affected NSCLC care, particularly the use of granulocyte colony-stimulating factor (G-CSF). Diagnosis and treatment of N...
Breast cancer risk with HRT, statins and colorectal cancer, and SBRT for lung metastases
November 03, 2020 09:00 - 9 minutes - 12.6 MBNews from MDedge Hematology-Oncology: New estimates for breast cancer risk with HRT: https://bit.ly/37VT0Pt BMJ study: https://bit.ly/2TKDIVt Lancet meta-analysis: https://bit.ly/3kUdbRl Single and multifraction SBRT found comparable for lung metastases: https://bit.ly/2HS36pR Statins may lower risk of colorectal cancer: https://bit.ly/3kLbR37 Email Blood & Cancer at [email protected]. Follow us on Twitter @MDedgeHemOnc.
How to use antiemetics: Dr. Paul Hesketh reviews ASCO’s guidelines on antiemetic use in cancer patients receiving checkpoint inhibitors or antineoplastic agents
October 29, 2020 08:00 - 25 minutes - 37.6 MBIn this episode, we review the latest guidelines on antiemetics from the American Society of Clinical Oncology (ASCO). Host David H. Henry, MD, is joined by ASCO guideline author Paul J. Hesketh, MD, of Lahey Hospital and Medical Center in Burlington, Mass. Dr. Hesketh explains the recommendations for antiemetic use in cancer patients receiving checkpoint inhibitors (CPIs) or high-, moderate-, or low-emetic-risk antineoplastic agents. Checkpoint inhibitors The update to ASCO’s gu...
Patients gain access to clinical notes, lung cancer screening guidelines fall short, and AML standard remains elusive
October 27, 2020 08:00 - 7 minutes - 10.2 MBHematology-Oncology News: National lung cancer screening guidelines may miss younger African American individuals at high risk: https://bit.ly/3e2CmhV Standard treatment lacking in relapsed / refractory AML: https://bit.ly/3kzoUVh (03:08) Patients can read your clinical notes starting Nov. 2: https://bit.ly/3mnuudL (05:40) You can email the show at [email protected].
Patients will gain access to clinical notes, lung cancer screening guidelines fall short, and AML standard remains elusive
October 27, 2020 08:00 - 7 minutes - 10.2 MBHematology-Oncology News: National lung cancer screening guidelines may miss younger African American individuals at high risk: https://bit.ly/3e2CmhV Standard treatment lacking in relapsed / refractory AML: https://bit.ly/3kzoUVh (03:08) Patients can read your clinical notes starting Nov. 2: https://bit.ly/3mnuudL (05:40) Update: The deadline for "open notes" has been extended to April 5, 2021. You can email the show at [email protected].
Hematology case review: Suspected ITP, presumed heparin-induced thrombocytopenia, and an ‘interesting’ case of anemia
October 22, 2020 08:00 - 27 minutes - 37.8 MBIn this episode, we review three hematology cases. One case illustrates the work-up and treatment of immune thrombocytopenia (ITP). Another case demonstrates how to diagnose and manage heparin-induced thrombocytopenia (HIT). And the final case is a patient who presented with anemia, a new mitral valve murmur, and mild splenomegaly. Host David H. Henry, MD, reviews these cases with three residents from Pennsylvania Hospital in Philadelphia – Sheila De Young, DO; Ronak Mistry, DO; and Deb...
Choosing surgery for older breast cancer patients, delayed screening from COVID-19 could increase deaths, and blood group O linked to decreased SARS-CoV-2 risk
October 20, 2020 08:00 - 10 minutes - 14.7 MBHematology Oncology News: Study advances personalized treatment for older breast cancer patients (https://bit.ly/3dHieSk) Delayed cancer screening could cause increase in deaths, study says (https://bit.ly/34afIAS) Blood group O linked to decreased risk of SARS-CoV-2 infection (https://bit.ly/2T8qilF) Email Blood & Cancer at [email protected] or follow us on Twitter @MDedgeHemOnc.
TERAVOLT registry sheds light on characteristics, treatment, and outcomes of patients with thoracic cancers and COVID-19
October 15, 2020 08:00 - 20 minutes - 28.1 MBHow do patients with thoracic cancers fare when they develop COVID-19? The researchers behind the TERAVOLT registry are trying to find out. TERAVOLT investigator Alessio Cortellini, MD, of the University of L’Aquila (Italy), joined host David Henry, MD, to discuss the TERAVOLT registry and its findings, which were recently presented at the European Society for Medical Oncology Virtual Congress 2020. What is TERAVOLT? TERAVOLT is an international registry of patients with thoracic cance...
FDA approves combo immunotherapy for mesothelioma, atezolizumab strikes out in ovarian cancer, and more
October 13, 2020 08:00 - 11 minutes - 17.8 MBHematology-Oncology News: Radiotherapy planning scans reveal breast cancer patients’ CVD risk (https://bit.ly/2FeoJiH) FDA OKs combination immunotherapy for first-line mesothelioma treatment (https://bit.ly/2Ff77mS) Apatinib plus gefitinib: Better PFS but more toxicity (https://bit.ly/34IyVsn) Atezolizumab strikes out in ovarian cancer (https://bit.ly/3iPjXG1) Email Blood & Cancer at [email protected] and learn more at https://www.mdedge.com/podcasts/blood-cancer
The psychiatry of cancer, a crossover from the Psychcast
October 08, 2020 11:37 - 29 minutes - 41.8 MBLorenzo Norris, MD, host of Psychcast, joins Blood & Cancer host David Henry, MD, to discuss steps clinicians can take to alleviate the distress associated with receiving a diagnosis of cancer. Dr. Norris is director of consult liaison psychiatry at George Washington University, Washington. Dr. Henry is clinical professor of medicine at the University of Pennsylvania, Philadelphia. Both doctors have no disclosures. A full transcript of this episode is available here: A conversation on m...
Global stomach cancer deaths decline but colorectal cancer deaths stagnate; plus, divergent results for paclitaxel/nab-paclitaxel for triple negative breast cancer
October 06, 2020 08:00 - 11 minutes - 15.3 MBHematology-Oncology News: Divergent findings with paclitaxel and nab-paclitaxel in TNBC (https://bit.ly/33vemjS) Palbociclib plus letrozole improves PFS in advanced endometrial cancer (https://bit.ly/2GIUl08) Global stomach cancer deaths decline as colorectal cancer deaths stagnate, rise (https://bit.ly/33zBVs1) You can email the show at [email protected] and you can learn more about the show at https://www.mdedge.com/podcasts/blood-cancer
ESMO 2020: Late-breaking and practice-changing studies on COVID-19 and breast, lung, gastrointestinal, and other cancers
October 01, 2020 08:00 - 59 minutes - 81.4 MBThere were a number of practice-changing and ground-breaking studies presented at the ESMO 2020 Virtual Congress, according to our guest in this episode. Alan P. Lyss, MD, subprincipal investigator for Heartland Cancer Research NCORP, joined host David H. Henry, MD, to review highlights from ESMO 2020. The pair discussed studies on gynecologic, breast, lung, gastrointestinal, and genitourinary cancers, as well as studies of anemia and COVID-19 in cancer patients. COVID-19 and cancer ...
Hem-Onc News: No benefit from postop radiotherapy in NSCLC; sotorasib is a 'triumph of drug discovery'; and choosing TKI for ALL
September 29, 2020 08:00 - 13 minutes - 18.7 MBHematology-Oncology News: No benefit with postoperative radiotherapy in stage IIIA2 NSCLC (https://bit.ly/3i1196r) ESMO meeting abstract: https://bit.ly/2RZwig4 First-in-class ADC ups survival in mTNBC (https://bit.ly/2GaoVQ2) ASCENT study: https://bit.ly/2Ey54df Sotorasib is a 'triumph of drug discovery' in cancer (https://bit.ly/2FQwpIt) CodeBreak100 trial: https://bit.ly/342dJNV TKI choice key for fit/unfit patients with Ph+ALL (https://bit.ly/3kLdmOs) Email Blood & Cancer at p...
Hem-Onc News: No benefit from postop radiotherapy in NSCLC, sotorasib is a 'triumph of drug discovery,' and choosing a TKI for ALL
September 29, 2020 08:00 - 13 minutes - 18.7 MBHematology-Oncology News: No benefit with postoperative radiotherapy in stage IIIA2 NSCLC (https://bit.ly/3i1196r) First-in-class ADC ups survival in mTNBC (https://bit.ly/2GaoVQ2) Sotorasib is a 'triumph of drug discovery' in cancer (https://bit.ly/2FQwpIt) TKI choice key for fit/unfit patients with Ph+ALL (https://bit.ly/3kLdmOs) Email Blood & Cancer at [email protected]
Studying cancer patients with COVID-19: Dr. Brian Rini describes the NCCAPS and CCC19 studies and reviews the latest findings
September 24, 2020 08:00 - 23 minutes - 33.6 MBHow do patients fare when they have cancer and COVID-19? Researchers developed the COVID-19 and Cancer Consortium (CCC19) and the National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) to gain some insight. In this episode, Brian Rini, MD, a professor of medicine at Vanderbilt University Medical Center, Nashville, Tenn., and host of The Uromigos podcast, explains what CCC19 and NCCAPS are. He also discusses findings from CCC19 that were presented at the European Society of Me...